A retrospective nationwide case study on the use of a new antifungal agent: Patients treated with caspofungin during 2001-2004 in Finland

Clinical Microbiology and Infection

Volumn 13, Issue 6, 2007, Pages 606-612

  Anttila, Veli Jukka ^a   Salonen, J ^b,c   Ylipalosaari, P ^d   Koivula, I ^e   Riikonen, P ^e   Nikoskelainen, J ^c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Aspergillosis; Candidiasis; Caspofungin; Efficacy; Invasive fungal infection; Safety

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ASPARAGINASE; CASPOFUNGIN; CLINDAMYCIN; CLONAZEPAM; CYCLOSPORIN A; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; METRONIDAZOLE; PHENOBARBITAL; PHENYTOIN; SULFONAMIDE; TRIMETHOPRIM; VANCOMYCIN; VORICONAZOLE;

ABNORMAL LABORATORY RESULT; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; APACHE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; CANDIDEMIA; CANDIDIASIS; CASE STUDY; CHILL; CREATININE BLOOD LEVEL; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; FINLAND; FLUSHING; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER FAILURE; LIVER NECROSIS; LIVER TOXICITY; MAGNESIUM BLOOD LEVEL; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MYCOSIS; NEPHROTOXICITY; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT;

EID: 34248329186     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01709.x     Document Type: Article

References (21)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
2. Lin S-J, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
3. Jantunen E, Volin L, Salonen O et al. Central nervous system aspergillosis in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2003; 31: 191-196.
4. Poikonen E, Lyytikäinen O, Anttila V-J, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003; 9: 985-990.
5. Almirante B, Rodriguez D, Park BJ et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-1835.
6. Morgan J, Wannenmuehler KA, Marr KA et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: Interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 (suppl 1): S49-S58.
7. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 2005; 41: 1232-1239.
8. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44-69.
9. McCormack PL, Perry CM. Caspofungin-a review of its use in the treatment of fungal infections. Drugs 2005; 65: 2049-2068.
10. Odds FC, Brown AJP, Gow NAR. Antifungal agents: Mechanism of action. Trends Microbiol 2003; 11: 272-279.
11. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47: 1068-1071.
12. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-2029.
13. Maertens J, Raad I, Petrikkos G et al. Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563-1571.
14. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
15. Glasmacher A, Cornely OA, Orlopp K et al. Caspofungin treatment in severely ill, immunocompromised patients: A case-documentation study of 118 patients. J Antimicrob Chemother 2006; 57: 127-134.
16. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
17. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771.
18. Hughes WT, Amstrong D, Bodey GP et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
19. Sable C, Nguyen B-YT, Chodakewitz JA, DiNubile MJ. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4: 25-30.
20. Marr KA, Hachem R, Papanicolauo G et al. Retrospective study of hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004; 6: 110-116.
21. Sanz-Rodriquez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transpl 2004; 34: 13-20.